The New York Times (5/13, Blum) reported the “telehealth start-up” Cerebral Inc., offers “services…entirely online” and “claimed to be able to provide prescriptions and counseling for conditions including depression, insomnia and” attention-deficit/hyperactivity disorder (AD/HD). Recently, however, “after reports that the company pressured its clinicians to prescribe medications for” AD/HD, the company “received a grand jury subpoena from the U.S. attorney’s office for the Eastern District of New York, which is investigating possible violations of the Controlled Substances Act, according to a representative for the company.” This investigation “comes on the heels of accusations from former employees who said the company prescribed Adderall” (dextroamphetamine-amphetamine) and “Ritalin [methylphenidate hydrochloride] to treat” AD/HD “without properly screening patients.”
Related Links:
— “The Hazards of Prescribing A.D.H.D. Drugs Online “Dani Blum, The New York Times, May 13, 2022